Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2002

View Archived Issues

Exclusive rights to key P. falciparum protein obtained by AdProTech

Hydro Med accelerates phase III development of Histrelin implant

Ciclesonide: site-activated inhaled corticosteroid with a promising profile for asthma Rx

Low-molecular-weight compound restores function of the p53 gene

Calpain inhibitor selected for development in ocular diseases

Specific ROCK inhibitor with potential as a novel glaucoma treatment

Anti-VEGF aptamer improves vision without adverse events in AMD patients

Edaravone should be evaluated in humans for ocular oxidative stress according to preclinical data

KL-6 is an effective serum marker for interstitial lung diseases

Onyx shifts business emphasis to clinical development

NeuroSearch and GSK discontinue development of NS-2389

AstraZeneca submits sNDA for Arimidex in early breast cancer

Hybridon initiates phase I/II trial of GEM-231/irinotecan in solid tumors

Interleukin Genetics and UAMS collaborate in Alzheimer's disease

SuperGen and Abbott conclude alliance

Ribozyme and Fujirebio collaborate to develop ribozyme-based clinical diagnostics

Zetiq identifies new potential colon cancer drug candidates

TRK-820 effective against both antihistamine-sensitive and -resistant pruritus

TZT-1027 exhibits enhanced activity against cytokine-secreting tumors

B7 protein PD-L2 described in patent

Complexes for use in in vivo diagnosis of hepatic fibrosis or necrosis

Vitronectin receptor antagonists for use in osteoporosis, etc.

Antagonists of NK1 receptors for use in irritable bowel syndrome and other GI disorders

Synaptic identifies new compounds for eating disorders

Zinc hydrolase inhibitors for use in ECE-mediated conditions

Compounds identified by Bayer with potential in ischemia-reperfusion injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...